Development of Antibacterial Drugs to Combat Drug-Resistant Bacteria
A special issue of Pharmaceuticals (ISSN 1424-8247). This special issue belongs to the section "Pharmacology".
Deadline for manuscript submissions: 31 January 2025 | Viewed by 150
Special Issue Editor
Interests: drug-resistant bacteria; antimicrobial resistance; new therapeutic solutions; improvement of existing therapies and alterantive therapies, such as autovaccines or bacteriophage therapy
Special Issues, Collections and Topics in MDPI journals
Special Issue Information
Dear Colleagues,
Antimicrobial resistance is responsible for more than 35,000 deaths per year in the EU/EEA and imposes significant costs, particularly on healthcare systems. In July 2022 the Commission, together with the Member States, recognized antimicrobial resistance as one of the most serious health threats. Overall, recent data suggest a significant upward trend in infections and associated deaths in almost all combinations of ‘antibiotic resistance’, particularly in healthcare settings. The consequence of the use of antibiotics is not only the selection of antibiotic-resistant microorganisms, but also a negative impact on the human body as a whole in the form of various side effects. Since the constant growth of the antibiotic resistance of microorganisms is becoming a global problem, the development of new therapeutic solutions, including alternatives to antimicrobial drugs, or the improvement of existing ones is urgently needed.
What are the best next steps? Are there promising clinical trials that keep in mind the serious expectation that antimicrobial resistance (AMR) will kill up to 10 million people a year by 2050? Sharing your research and your thoughts can solve this major healthcare issue.
Dr. Adriána Liptáková
Guest Editor
Manuscript Submission Information
Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All submissions that pass pre-check are peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as short communications are invited. For planned papers, a title and short abstract (about 100 words) can be sent to the Editorial Office for announcement on this website.
Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. Pharmaceuticals is an international peer-reviewed open access monthly journal published by MDPI.
Please visit the Instructions for Authors page before submitting a manuscript. The Article Processing Charge (APC) for publication in this open access journal is 2900 CHF (Swiss Francs). Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.
Keywords
- development of antibacterial drugs
- drug-resistant bacteria
- antimicrobial resistance
- new therapeutic solutions
- improvement of existing therapies
- nosocomial infections
